2026-2034年全球气喘和慢性阻塞性肺病（COPD）市场规模、份额、趋势和成长分析报告

预计气喘和慢性阻塞性肺病市场将从 2025 年的 422.5 亿美元成长到 2034 年的 654.4 亿美元，2026 年至 2034 年的复合年增长率为 4.98%。

受空气污染加剧、烟草消费量增加以及呼吸系统疾病盛行率上升的推动，全球气喘和慢性阻塞性肺病（COPD）市场正经历显着增长。都市化和工业化加剧了空气品质恶化，导致诊断率上升。製药公司正投资研发创新吸入器、生物製药和联合治疗，以改善疾病管理。

关键成长要素包括生物目标疗法的进步、医疗保健支出的增加以及政府对意识提升的支持。具备数位化监测功能的智慧吸入器的推出提高了患者的用药依从性和治疗效果。扩大临床研究和增加学名药的供应进一步增强了市场竞争力。

展望未来，由于个人化治疗方案的广泛应用和诊断能力的提升，市场预计将持续成长。随着医疗基础设施的不断完善，新兴市场预计将迎来强劲成长。对长效支气管扩张剂和抗发炎药物的持续研究将塑造未来的市场格局，并提升长期获利能力。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章 全球气喘与慢性阻塞性肺病（COPD）市场：依疾病分类

• 市场分析、洞察与预测
• 气喘
• COPD

第五章 全球气喘与慢性阻塞性肺病（COPD）市场：依药物分类

• 市场分析、洞察与预测
• 组合药物
• 短效β受体激动剂（SABA）
• 长效β2受体激动剂（LABA）
• 白三烯拮抗剂（LTAs）
• 抗胆碱能促效剂
• 其他的

第六章 全球气喘和慢性阻塞性肺病（COPD）市场：按地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第七章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第八章：公司简介

• 主要公司的市占率分析
• 公司简介
  • GlaxoSmithKline Plc
  • AstraZeneca Plc
  • Hoffmann-La Roche Ltd
  • Vectura Group Plc
  • Organon
  • Abbott Laboratories
  • Boehringer Ingelheim International GmbH
  • Teva Pharmaceutical Industries Ltd
  • Novartis AG
  • Sanofi

The Asthma And COPD Market size is expected to reach USD 65.44 Billion in 2034 from USD 42.25 Billion (2025) growing at a CAGR of 4.98% during 2026-2034.

The Global Asthma And COPD Market is witnessing substantial growth driven by rising air pollution levels, increasing tobacco consumption, and growing prevalence of respiratory disorders. Urbanization and industrialization have contributed to deteriorating air quality, leading to higher diagnosis rates. Pharmaceutical companies are investing in innovative inhalers, biologics, and combination therapies to enhance disease management.

Major growth drivers include advancements in targeted biologic therapies, increased healthcare spending, and supportive government initiatives for respiratory health awareness. The introduction of smart inhalers with digital monitoring features is improving patient adherence and treatment outcomes. Growing clinical research and expansion of generic drug availability are further strengthening market competitiveness.

Looking forward, the market is poised for continued expansion with rising adoption of personalized treatment approaches and improved diagnostic capabilities. Emerging economies are expected to witness strong growth due to expanding healthcare infrastructure. Ongoing research in long-acting bronchodilators and anti-inflammatory agents will likely shape the future landscape and enhance long-term revenue potential.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Diseases

• Asthma
• COPD

By Medication Class

• Combination Drugs
• Short Acting Beta Agonists (SABA)
• Long Acting Beta Agonists (LABA)
• Leukotriene Antagonists (LTA)
• Anticholinergics
• Others

COMPANIES PROFILED

• GlaxoSmithKline Plc, AstraZeneca Plc, HoffmannLa Roche Ltd, Vectura Group Plc, Organon, Abbott Laboratories, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd, Novartis AG, Sanofi
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ASTHMA AND COPD MARKET: BY DISEASES 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Diseases
• 4.2. Asthma Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. COPD Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ASTHMA AND COPD MARKET: BY MEDICATION CLASS 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Medication Class
• 5.2. Combination Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Short Acting Beta Agonists (SABA) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Long Acting Beta Agonists (LABA) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Leukotriene Antagonists (LTA) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Anticholinergics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ASTHMA AND COPD MARKET: BY REGION 2022-2034(USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Diseases
  • 6.2.2 By Medication Class
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Diseases
  • 6.3.2 By Medication Class
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Diseases
  • 6.4.2 By Medication Class
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Diseases
  • 6.5.2 By Medication Class
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 South East Asia
  • 6.5.8 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Diseases
  • 6.6.2 By Medication Class
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL ASTHMA AND COPD INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 GlaxoSmithKline Plc
  • 8.2.2 AstraZeneca Plc
  • 8.2.3 Hoffmann-La Roche Ltd
  • 8.2.4 Vectura Group Plc
  • 8.2.5 Organon
  • 8.2.6 Abbott Laboratories
  • 8.2.7 Boehringer Ingelheim International GmbH
  • 8.2.8 Teva Pharmaceutical Industries Ltd
  • 8.2.9 Novartis AG
  • 8.2.10 Sanofi